Study S001399

A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Saudi Arabia

ClinicalTrials.gov record

Registration

Registration: NCT05230589
Acronym: PIONEER REAL
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 194
Start: 2022-04-25
Primary completion: 2023-03-13
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Oral semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1240-3898

Registered primary outcomes

Change in Glycated haemoglobin (HbA1c ) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.